タカギ トシオ
Takagi Toshio
高木 敏男 所属 医学部 医学科(東京女子医科大学病院) 職種 教授・基幹分野長 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読なし |
表題 | Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. |
掲載誌名 | 正式名:In vivo (Athens, Greece) 略 称:In Vivo ISSNコード:17917549/0258851X |
掲載区分 | 国外 |
巻・号・頁 | 31(4),pp.769-771 |
著者・共著者 | KOBARI Yuki, KONDO Tsunenori*, TAKAGI Toshio, OMAE Kenji, NAKAZAWA Hayakazu, TANABE Kazunari |
発行年月 | 2017/07 |
概要 | BACKGROUND/AIM:Rapid progressive disease (RPD), accelerated tumour growth immediate after the initiation of immune checkpoint inhibitor therapy, has been reported in melanoma and lung cancer. Herein, we describe 3 cases of RPD during the initial phase of nivolumab treatment for metastatic renal cell carcinoma.PATIENTS AND METHODS:The first and second patients received nivolumab in the fourth-line setting. The third patient received nivolumab therapy as third-line treatment.RESULTS:The first patient developed severe respiratory failure due to carcinomatous lymphangiosis 14 days after initiation of nivolumab therapy. The second patient developed leg paraplegia due to rapid growth of the metastatic tumour at the sixth thoracic vertebrae 5 days later. The third patient developed grade 4 hypercalcemia due to RPD on day 3.CONCLUSION:Clinicians should be aware of RPD during the initial phase of nivolumab therapy, especially in patients with critical lesions in the late-line setting. |
DOI | 10.21873/invivo.11129 |
PMID | 28652455 |